{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:11:26Z","timestamp":1785323486399,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["19-74-30007"],"award-info":[{"award-number":["19-74-30007"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05349-8","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:14:08Z","timestamp":1763018048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Potential of HAEEPGP Peptide Against \u03b2-Amyloid Induced Neuropathology"],"prefix":"10.1007","volume":"63","author":[{"given":"Olga I.","family":"Kechko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina A.","family":"Mukhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry V.","family":"Yanvarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana Yu.","family":"Eremina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga A.","family":"Katkova-Zhukotskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill D.","family":"Chaprov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina S.","family":"Drutskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey A.","family":"Kozin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir A.","family":"Mitkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"21","key":"5349_CR1","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.3390\/cells11213421","volume":"11","author":"L Busch","year":"2022","unstructured":"Busch L, Eggert S, Endres K, Bufe B (2022) The hidden role of non-canonical amyloid \u03b2 isoforms in Alzheimer\u2019s disease. Cells 11(21):3421. https:\/\/doi.org\/10.3390\/cells11213421","journal-title":"Cells"},{"issue":"2","key":"5349_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab028","volume":"3","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Perez KA, Lago LC, Klatt S, McLean CA, Birchall IE, Barnham KJ, Masters CL, et al. (2021) Quantification of N-terminal amyloid-\u03b2 isoforms reveals isomers are the most abundant form of the amyloid-\u03b2 peptide in sporadic Alzheimer\u2019s disease. Brain Commun 3(2):fcab028. https:\/\/doi.org\/10.1093\/braincomms\/fcab028","journal-title":"Brain Commun"},{"issue":"8","key":"5349_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/cells8080771","volume":"8","author":"EP Barykin","year":"2019","unstructured":"Barykin EP, Garifulina AI, Kruykova EV, Spirova EN, Anashkina AA, Adzhubei AA, Shelukhina IV, Kasheverov IE, et al. (2019) Isomerization of Asp7 in beta-amyloid enhances inhibition of the \u03b17 nicotinic receptor and promotes neurotoxicity. Cells 8(8):771. https:\/\/doi.org\/10.3390\/cells8080771","journal-title":"Cells"},{"issue":"1","key":"5349_CR4","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1038\/s41598-018-21815-x","volume":"8","author":"OG Zatsepina","year":"2018","unstructured":"Zatsepina OG, Kechko OI, Mitkevich VA, Kozin SA, Yurinskaya MM, Vinokurov MG, Serebryakova MV, Rezvykh AP, et al. (2018) Amyloid-\u03b2 with isomerized Asp7 cytotoxicity is coupled to protein phosphorylation. Sci Rep 8(1):3518. https:\/\/doi.org\/10.1038\/s41598-018-21815-x","journal-title":"Sci Rep"},{"issue":"3","key":"5349_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12640-013-9399-y","volume":"24","author":"SA Kozin","year":"2013","unstructured":"Kozin SA, Cheglakov IB, Ovsepyan AA, Telegin GB, Tsvetkov PO, Lisitsa AV, Makarov AA (2013) Peripherally applied synthetic peptide isoAsp7-A\u03b2(1\u201342) triggers cerebral \u03b2-amyloidosis. Neurotox Res 24(3):370\u2013376. https:\/\/doi.org\/10.1007\/s12640-013-9399-y","journal-title":"Neurotox Res"},{"issue":"11","key":"5349_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.492","volume":"4","author":"VA Mitkevich","year":"2013","unstructured":"Mitkevich VA, Petrushanko IY, Yegorov YE, Simonenko OV, Vishnyakova KS, Kulikova AA, Tsvetkov PO, Makarov AA, et al. (2013) Isomerization of Asp7 leads to increased toxic effect of amyloid-\u03b242 on human neuronal cells. Cell Death Dis 4(11):e939. https:\/\/doi.org\/10.1038\/cddis.2013.492","journal-title":"Cell Death Dis"},{"issue":"6","key":"5349_CR7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1212\/CON.0000000000001503","volume":"30","author":"DS Geldmacher","year":"2024","unstructured":"Geldmacher DS (2024) Treatment of Alzheimer disease. Continuum (Minneap Minn) 30(6):1823\u20131844. https:\/\/doi.org\/10.1212\/CON.0000000000001503","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"5349_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W (2023) Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther 8(1):248. https:\/\/doi.org\/10.1038\/s41392-023-01484-7","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"5349_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae435","volume":"6","author":"M Aljuhani","year":"2024","unstructured":"Aljuhani M, Ashraf A, Edison P (2024) Evaluating clinical meaningfulness of anti-\u03b2-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer\u2019s disease. Brain Commun 6(6):fcae435. https:\/\/doi.org\/10.1093\/braincomms\/fcae435","journal-title":"Brain Commun"},{"issue":"11","key":"5349_CR10","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.3390\/biomedicines12112636","volume":"12","author":"X Qi","year":"2024","unstructured":"Qi X, Nizamutdinov D, Yi SS, Wu E, Huang JH (2024) Disease modifying monoclonal antibodies and symptomatic pharmacological treatment for Alzheimer\u2019s disease. Biomedicines 12(11):2636. https:\/\/doi.org\/10.3390\/biomedicines12112636","journal-title":"Biomedicines"},{"issue":"12","key":"5349_CR11","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/s0196-9781(02)00261-9","volume":"23","author":"WA Banks","year":"2002","unstructured":"Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002) Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer\u2019s disease. Peptides 23(12):2223\u20132226. https:\/\/doi.org\/10.1016\/s0196-9781(02)00261-9","journal-title":"Peptides"},{"issue":"1","key":"5349_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12987-022-00398-w","volume":"19","author":"U Julku","year":"2022","unstructured":"Julku U, Xiong M, Wik E, Roshanbin S, Sehlin D, Syv\u00e4nen S (2022) Brain pharmacokinetics of mono- and bispecific amyloid-\u03b2 antibodies in wild-type and Alzheimer\u2019s disease mice measured by high cut-off microdialysis. Fluids Barriers CNS 19(1):99. https:\/\/doi.org\/10.1186\/s12987-022-00398-w","journal-title":"Fluids Barriers CNS"},{"key":"5349_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.125055","volume":"669","author":"S Mojarad-Jabali","year":"2025","unstructured":"Mojarad-Jabali S, Roh KH (2025) Peptide-based inhibitors and nanoparticles: emerging therapeutics for Alzheimer\u2019s disease. Int J Pharm 669:125055. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.125055","journal-title":"Int J Pharm"},{"key":"5349_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fnagi.2018.00021","volume":"10","author":"MH Baig","year":"2018","unstructured":"Baig MH, Ahmad K, Rabbani G, Choi I (2018) Use of peptides for the management of Alzheimer\u2019s disease: diagnosis and inhibition. Front Aging Neurosci 10:21. https:\/\/doi.org\/10.3389\/fnagi.2018.00021","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"5349_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/10738584211016409","volume":"29","author":"IFL Mota","year":"2023","unstructured":"Mota IFL, de Lima LS, Santana BM, Gobbo GAM, Bicca JVML, Azevedo JRM, Veras LG, Taveira RAA, et al. (2023) Alzheimer\u2019s disease: innovative therapeutic approaches based on peptides and nanoparticles. Neuroscientist 29(1):78\u201396. https:\/\/doi.org\/10.1177\/10738584211016409","journal-title":"Neuroscientist"},{"issue":"2","key":"5349_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/molecules23020283","volume":"23","author":"S Ribari\u010d","year":"2018","unstructured":"Ribari\u010d S (2018) Peptides as potential therapeutics for Alzheimer\u2019s disease. Molecules 23(2):283. https:\/\/doi.org\/10.3390\/molecules23020283","journal-title":"Molecules"},{"issue":"4","key":"5349_CR17","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3233\/JAD-150031","volume":"46","author":"PO Tsvetkov","year":"2015","unstructured":"Tsvetkov PO, Cheglakov IB, Ovsepyan AA, Mediannikov OY, Morozov AO, Telegin GB, Kozin SA (2015) Peripherally applied synthetic tetrapeptides HAEE and RADD slow down the development of cerebral \u03b2-amyloidosis in A\u03b2PP\/PS1 transgenic mice. J Alzheimers Dis 46(4):849\u2013853. https:\/\/doi.org\/10.3233\/JAD-150031","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"5349_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.14336\/AD.2022.0827","volume":"14","author":"VA Mitkevich","year":"2023","unstructured":"Mitkevich VA, Barykin EP, Eremina S, Pani B, Katkova-Zhukotskaya O, Polshakov VI, Adzhubei AA, Kozin SA, et al. (2023) Zn-dependent \u03b2-amyloid aggregation and its reversal by the tetrapeptide HAEE. Aging Dis 14(2):309\u2013318. https:\/\/doi.org\/10.14336\/AD.2022.0827","journal-title":"Aging Dis"},{"issue":"17","key":"5349_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176272","volume":"21","author":"EP Barykin","year":"2020","unstructured":"Barykin EP, Garifulina AI, Tolstova AP, Anashkina AA, Adzhubei AA, Mezentsev YV, Shelukhina IV, Kozin SA, et al. (2020) Tetrapeptide Ac-HAEE-NH2 protects \u03b14\u03b22 nAChR from inhibition by A\u03b2. Int J Mol Sci 21(17):6272. https:\/\/doi.org\/10.3390\/ijms21176272","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5349_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0197-0186(02)00050-5","volume":"41","author":"WL Klein","year":"2002","unstructured":"Klein WL (2002) Abeta toxicity in Alzheimer\u2019s disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41(5):345\u2013352. https:\/\/doi.org\/10.1016\/s0197-0186(02)00050-5","journal-title":"Neurochem Int"},{"issue":"24","key":"5349_CR21","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.1111\/febs.15320","volume":"287","author":"SS Mariasina","year":"2020","unstructured":"Mariasina SS, Chang CF, Petrova OA, Efimov SV, Klochkov VV, Kechko OI, Mitkevich VA, Sergiev PV, et al. (2020) Williams-beuren syndrome-related methyltransferase WBSCR27: cofactor binding and cleavage. FEBS J 287(24):5375\u20135393. https:\/\/doi.org\/10.1111\/febs.15320","journal-title":"FEBS J"},{"issue":"1","key":"5349_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/genetics\/77.1.71","volume":"77","author":"S Brenner","year":"1974","unstructured":"Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77(1):71\u201394. https:\/\/doi.org\/10.1093\/genetics\/77.1.71","journal-title":"Genetics"},{"issue":"5","key":"5349_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nrg794","volume":"3","author":"EM Jorgensen","year":"2002","unstructured":"Jorgensen EM, Mango SE (2002) The art and design of genetic screens: Caenorhabditis elegans. Nat Rev Genet 3(5):356\u2013369. https:\/\/doi.org\/10.1038\/nrg794","journal-title":"Nat Rev Genet"},{"issue":"5594","key":"5349_CR24","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1126\/science.1074240","volume":"298","author":"A Dillin","year":"2002","unstructured":"Dillin A, Crawford DK, Kenyon C (2002) Timing requirements for insulin\/IGF-1 signaling in C. elegans. Science 298(5594):830\u2013834. https:\/\/doi.org\/10.1126\/science.1074240","journal-title":"Science"},{"issue":"6763","key":"5349_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/45544","volume":"402","author":"J Apfeld","year":"1999","unstructured":"Apfeld J, Kenyon C (1999) Regulation of lifespan by sensory perception in Caenorhabditis elegans. Nature 402(6763):804\u2013809. https:\/\/doi.org\/10.1038\/45544","journal-title":"Nature"},{"issue":"4","key":"5349_CR26","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2012.12.043","volume":"152","author":"I Gusarov","year":"2013","unstructured":"Gusarov I, Gautier L, Smolentseva O, Shamovsky I, Eremina S, Mironov A, Nudler E (2013) Bacterial nitric oxide extends the lifespan of C. elegans. Cell 152(4):818\u2013830. https:\/\/doi.org\/10.1016\/j.cell.2012.12.043","journal-title":"Cell"},{"key":"5349_CR27","doi-asserted-by":"publisher","first-page":"1362581","DOI":"10.3389\/fnmol.2024.1362581","volume":"17","author":"KB Varshavskaya","year":"2024","unstructured":"Varshavskaya KB, Petrushanko IY, Mitkevich VA, Barykin EP, Makarov AA (2024) Post-translational modifications of beta-amyloid alter its transport in the blood-brain barrier in vitro model. Front Mol Neurosci 17:1362581. https:\/\/doi.org\/10.3389\/fnmol.2024.1362581","journal-title":"Front Mol Neurosci"},{"issue":"6","key":"5349_CR28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/biom11060909","volume":"11","author":"YA Zolotarev","year":"2021","unstructured":"Zolotarev YA, Mitkevich VA, Shram SI, Adzhubei AA, Tolstova AP, Talibov OB, Dadayan AK, Myasoyedov NF, et al. (2021) Pharmacokinetics and molecular modeling indicate nAChR\u03b14-derived peptide HAEE goes through the blood-brain barrier. Biomolecules 11(6):909. https:\/\/doi.org\/10.3390\/biom11060909","journal-title":"Biomolecules"},{"issue":"3","key":"5349_CR29","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/brain\/aww349","volume":"140","author":"Z Fan","year":"2017","unstructured":"Fan Z, Brooks DJ, Okello A, Edison P (2017) An early and late peak in microglial activation in Alzheimer\u2019s disease trajectory. Brain 140(3):792\u2013803. https:\/\/doi.org\/10.1093\/brain\/aww349","journal-title":"Brain"},{"issue":"1","key":"5349_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1288-0","volume":"15","author":"C Dello Russo","year":"2018","unstructured":"Dello Russo C, Cappoli N, Coletta I, Mezzogori D, Paciello F, Pozzoli G, Navarra P, Battaglia A (2018) The human microglial HMC3 cell line: where do we stand? A systematic literature review. J Neuroinflammation 15(1):259. https:\/\/doi.org\/10.1186\/s12974-018-1288-0","journal-title":"J Neuroinflammation"},{"issue":"4","key":"5349_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00726-006-0328-8","volume":"30","author":"YA Zolotarev","year":"2006","unstructured":"Zolotarev YA, Dolotov OV, Inozemtseva LS, Dadayan AK, Dorokhova EM, Andreeva LA, Alfeeva LY, Grivennikov IA, et al. (2006) Degradation of the ACTH(4\u201310) analog Semax in the presence of rat basal forebrain cell cultures and plasma membranes. Amino Acids 30(4):403\u2013408. https:\/\/doi.org\/10.1007\/s00726-006-0328-8","journal-title":"Amino Acids"},{"key":"5349_CR32","doi-asserted-by":"publisher","first-page":"1089005","DOI":"10.3389\/fnagi.2023.1089005","volume":"15","author":"O Zhukov","year":"2023","unstructured":"Zhukov O, He C, Soylu-Kucharz R, Cai C, Lauritzen AD, Aldana BI, Bj\u00f6rkqvist M, Lauritzen M, et al. (2023) Preserved blood-brain barrier and neurovascular coupling in female 5xFAD model of Alzheimer\u2019s disease. Front Aging Neurosci 15:1089005. https:\/\/doi.org\/10.3389\/fnagi.2023.1089005","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"5349_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/biom12030399","volume":"12","author":"K Gnoth","year":"2022","unstructured":"Gnoth K, Geissler S, Feldhaus J, Taudte N, Ilse V, Z\u00fcrner S, Greiser S, Braumann UD, et al. (2022) Evidence for enhanced efficacy of passive immunotherapy against beta-amyloid in CD33-negative 5xFAD mice. Biomolecules 12(3):399. https:\/\/doi.org\/10.3390\/biom12030399","journal-title":"Biomolecules"},{"issue":"1","key":"5349_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/s0022-510x(98)00092-6","volume":"158","author":"MA Lovell","year":"1998","unstructured":"Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer\u2019s disease senile plaques. J Neurol Sci 158(1):47\u201352. https:\/\/doi.org\/10.1016\/s0022-510x(98)00092-6","journal-title":"J Neurol Sci"},{"issue":"1","key":"5349_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010072","volume":"25","author":"SA Kozin","year":"2023","unstructured":"Kozin SA, Kechko OI, Adzhubei AA, Makarov AA, Mitkevich VA (2023) Switching on\/off amyloid plaque formation in transgenic animal models of Alzheimer\u2019s disease. Int J Mol Sci 25(1):72. https:\/\/doi.org\/10.3390\/ijms25010072","journal-title":"Int J Mol Sci"},{"issue":"11","key":"5349_CR36","doi-asserted-by":"publisher","first-page":"7705","DOI":"10.1073\/pnas.092034699","volume":"99","author":"JY Lee","year":"2002","unstructured":"Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci USA 99(11):7705\u20137710. https:\/\/doi.org\/10.1073\/pnas.092034699","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"5349_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1570159X17666190704153807","volume":"18","author":"M Rychlik","year":"2020","unstructured":"Rychlik M, Mlyniec K (2020) Zinc-mediated neurotransmission in Alzheimer\u2019s disease: a potential role of the GPR39 in dementia. Curr Neuropharmacol 18(1):2\u201313. https:\/\/doi.org\/10.2174\/1570159X17666190704153807","journal-title":"Curr Neuropharmacol"},{"key":"5349_CR38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.neuroscience.2013.09.016","volume":"254","author":"Y Buskila","year":"2013","unstructured":"Buskila Y, Crowe SE, Ellis-Davies GC (2013) Synaptic deficits in layer 5 neurons precede overt structural decay in 5xFAD mice. Neuroscience 254:152\u2013159. https:\/\/doi.org\/10.1016\/j.neuroscience.2013.09.016","journal-title":"Neuroscience"},{"issue":"1","key":"5349_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13287-025-04324-3","volume":"16","author":"S Rao","year":"2025","unstructured":"Rao S, Madhu LN, Babu RS, Shankar G, Kotian S, Nagarajan A, Upadhya R, Narvekar E, et al. (2025) Extracellular vesicles from hiPSC-derived NSCs protect human neurons against A\u03b2-42 oligomers induced neurodegeneration, mitochondrial dysfunction and tau phosphorylation. Stem Cell Res Ther 16(1):191. https:\/\/doi.org\/10.1186\/s13287-025-04324-3","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"5349_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P (2021) Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol 17(3):157\u2013172. https:\/\/doi.org\/10.1038\/s41582-020-00435-y","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"5349_CR41","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11064-020-02990-8","volume":"46","author":"SM Kilbride","year":"2021","unstructured":"Kilbride SM, Telford JE, Davey GP (2021) Complex I controls mitochondrial and plasma membrane potentials in nerve terminals. Neurochem Res 46(1):100\u2013107. https:\/\/doi.org\/10.1007\/s11064-020-02990-8","journal-title":"Neurochem Res"},{"issue":"8006","key":"5349_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41586-024-07167-9","volume":"628","author":"L Peruzzotti-Jametti","year":"2024","unstructured":"Peruzzotti-Jametti L, Willis CM, Krzak G, Hamel R, Pirvan L, Ionescu RB, Reisz JA, Prag HA, et al. (2024) Mitochondrial complex I activity in microglia sustains neuroinflammation. Nature 628(8006):195\u2013203. https:\/\/doi.org\/10.1038\/s41586-024-07167-9","journal-title":"Nature"},{"key":"5349_CR43","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.bbi.2024.06.014","volume":"120","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Zhang J, Wu Y, Xie M, Tao S, Lv Q, Wang Q (2024) Plasma IL-6 levels and their association with brain health and dementia risk: a population-based cohort study. Brain Behav Immun 120:430\u2013438. https:\/\/doi.org\/10.1016\/j.bbi.2024.06.014","journal-title":"Brain Behav Immun"},{"issue":"1","key":"5349_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41398-021-01349-z","volume":"11","author":"E Lyra","year":"2021","unstructured":"Lyra E, Silva NM, Gon\u00e7alves RA, Pascoal TA, Lima-Filho RAS, Resende EPF, Vieira ELM, Teixeira AL, et al. (2021) Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer\u2019s disease. Transl Psychiatry 11(1):251. https:\/\/doi.org\/10.1038\/s41398-021-01349-z","journal-title":"Transl Psychiatry"},{"issue":"6","key":"5349_CR45","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41593-020-0624-8","volume":"23","author":"N Habib","year":"2020","unstructured":"Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D, et al. (2020) Disease-associated astrocytes in Alzheimer\u2019s disease and aging. Nat Neurosci 23(6):701\u2013706. https:\/\/doi.org\/10.1038\/s41593-020-0624-8","journal-title":"Nat Neurosci"},{"issue":"3","key":"5349_CR46","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/cells10030540","volume":"10","author":"P Preman","year":"2021","unstructured":"Preman P, Alfonso-Triguero M, Alberdi E, Verkhratsky A, Arranz AM (2021) Astrocytes in Alzheimer\u2019s disease: pathological significance and molecular pathways. Cells 10(3):540. https:\/\/doi.org\/10.3390\/cells10030540","journal-title":"Cells"},{"key":"5349_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.619626","volume":"12","author":"MD Monterey","year":"2021","unstructured":"Monterey MD, Wei H, Wu X, Wu JQ (2021) The many faces of astrocytes in Alzheimer\u2019s disease. Front Neurol 12:619626. https:\/\/doi.org\/10.3389\/fneur.2021.619626","journal-title":"Front Neurol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05349-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05349-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05349-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:14:09Z","timestamp":1763018049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05349-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5349"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05349-8","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Russian regulations on animal protection. Approval was granted by Local Bioethics Committee of the Center for Preclinical Testing of the Institute of Physiologically Active Compounds (IPAC RAS) at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences (Protocol No. 84 from September 20th, 2024) and by the Ethics Review Committee at the Engelhardt Institute of Molecular Biology, Russian Academy of Sciences (Protocol No. 1 from March 5th, 2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}